Heart drug dosing study launches for kids with duchenne

NCT ID NCT07172971

Recruiting now Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 4 times

Summary

This study will test how the heart drug empagliflozin is absorbed and processed in 10 children with Duchenne muscular dystrophy, ages 8 to 18. The goal is to find the best dose for protecting the heart in this rare disease. Participants will take the drug by mouth and have blood levels measured over 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin (SGLT-2 inhibitor)
What this could lead to: If successful, this study could help determine the right dose of empagliflozin to protect the heart in children with Duchenne muscular dystrophy.
What could go wrong: This is a very small, early-phase study (only 10 participants) focused on dosing, not on proving the drug works for heart problems. The drug is already used off-label, so results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy Duchenne muscular dystrophy heart failure muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY (DMD)

Contacts and locations

Locations

Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.